Skip to main content
TipRanks
Go Ultimate75% OFF

Heron Therapeutics (0J4V) Share Price & Analysis

3 Followers

0J4V Stock Chart & Stats

$0.28-$0.02(-6.95%)
At close: 4:30 PM GMT
$0.3$0.35$0.4Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.27 - $0.29
52-Week Range
$0.26 - $1.57
Previous Close
$0.30
Volume
N/A
Average Volume (3M)
131.41K
Market Cap
$53.70M
Enterprise Value
$169.18M
Total Cash (Recent Filing)
$23.45M
Total Debt (Recent Filing)
$131.73M
Price to Earnings (P/E)
―
Beta
1.75
Next Earnings
Mar 04, 2027 (Est.)
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

APONVIE Adoption And Share Gains

Rapid APONVIE sales, account growth, procedure coverage and share gains indicate expanding adoption in the surgical market. Continued penetration can diversify Heron’s commercial base and support a more durable acute-care growth engine beyond its established products.

High Gross Margin And Improving Operating Leverage

A gross margin near 70% provides meaningful contribution potential as product volumes grow, while improved adjusted EBITDA shows operating leverage is emerging. If maintained, this combination can narrow losses and strengthen the economics of Heron’s commercial portfolio.

Strategic Asset Sale Supports Liquidity

The asset sale creates a significant source of cash and additional contingent value, with proceeds designated to repay Heron’s working capital facility. Completing the transaction could reduce financing pressure while preserving potential participation in future ZYNRELEF economics.

Bears Say

Extreme Leverage And Fragile Capital Structure

Very high leverage leaves little equity protection against operating setbacks and limits financial flexibility. Debt service, refinancing and covenant demands can absorb resources that would otherwise fund commercialization, making the business more vulnerable during product or legal disruption.

CINVANTI Faces Generic-entry Risk

Potential generic competition threatens the durability of CINVANTI’s revenue and market position, especially because it is Heron’s largest product. Even with an appeal and defensive strategy, uncertain timing and pricing pressure could weaken cash generation and portfolio scale.

Persistent Losses And Negative Cash Generation

Moderating cash burn is encouraging, but continued negative operating and free cash flow means Heron is not yet self-funding. Ongoing losses increase reliance on asset monetization, financing or spending reductions and may constrain investment in sales expansion and growth initiatives.

Heron Therapeutics News

0J4V FAQ

What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest share price was $0.26 and its highest was $1.57 in the past 12 months.
What is Heron Therapeutics’s market cap?
Heron Therapeutics’s market cap is $53.70M.
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 106 days.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on Nov 09, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.025 by -$0.005.
Is Heron Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Heron Therapeutics dividends here
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Heron Therapeutics have?
Heron Therapeutics has 190,273,590 shares outstanding.
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.025. Following the earnings report the stock price went up 30.584%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Hedge funds hold Heron Therapeutics shares: the largest hedge-fund position in Heron Therapeutics is 1,299,100,773 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology